No improvement in clinical outcomes occurred among inpatients with COVID-19 who received nirtmatrelvir-ritonavir or molnupiravir in addition to usual care.

In a July 9 memo, the director of the FDA's Center for Biologics Evaluation and Research contended there was not enough ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research ...

A meta-analysis of 187 trials shows that Paxlovid and remdesivir reduce the risk for hospitalization in patients with mild-to ...

Background There is uncertainty about the associations of angiotensive enzyme (ACE) inhibitor and angiotensin receptor blocker (ARB) drugs with COVID-19 disease. We studied whether patients prescribed ...

disease. “Our study has provided the first evidence to prove PLpro is a powerful new drug target for COVID-19 treatments, while also showing its potential ability to treat the virus with unprecedented ...

Background: Drug repurposing has become a widely adopted strategy to minimise research time, costs, and associated risks. Combinations of protease inhibitors such as lopinavir and darunavir with ...

A new study from researchers at Wake Forest University School of Medicine is shedding light on how scientific evidence and the uncertainty surrounding three unproven therapeutics were portrayed by ...

COVID-19 is an infectious disease caused by SARS-CoV-2 leading to the ongoing global pandemic. Infected patients developed a range of respiratory symptoms, including respiratory failure, as well as ...

The constant evolution of new COVID-19 variants makes it critical for clinicians to have multiple therapies in their arsenal for treating drug-resistant infections. Researchers have now discovered ...